21:57 , Feb 14, 2019 |  BC Innovations  |  Emerging Company Profile

Indalo: Integral to fibrosis

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Antegrin, Cascadia deal

Antegrin and Cascadia merged to form Indalo Therapeutics Inc. (St. Louis, Mo.). The newco is developing treatments for fibrotic diseases affecting the kidney, liver, and lung using Antegrin’s portfolio of small molecule integrin antagonists, including...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

St. Louis University, Antegrin deal

The university granted Antegrin exclusive rights to “over a dozen” orally bioavailable pro-fibrotic integrins. Antegrin said the small molecule candidates are in preclinical development and that financials are not disclosed. St. Louis University , St....
07:00 , Jul 31, 2014 |  BC Innovations  |  Cover Story

Fresh air for COPD

An undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address the underlying pathology in chronic obstructive pulmonary disease by improving airway remodeling via suppressing transforming growth...
08:00 , Dec 5, 2013 |  BC Innovations  |  Cover Story

Targeting fibrotic integrin

Fibrosis has long been associated with the activation of transforming growth factor-b by integrin, but the mechanism underlying the process in vivo was not known. Now, an international team has shown that the myofibroblast-expressed integrin...
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Liver disease, pulmonary fibrosis Integrin aV (CD51) Studies in mice suggest a small molecule inhibitor of CD51 could help treat fibrosis. In mouse models of...
07:00 , May 29, 2001 |  BioCentury  |  Tools & Techniques

The pathways of Crohn's

Therapy for Crohn's disease is based on regimens of aminosalicylates, steroids, antibiotics, and periodic infusions of Remicade , an anti-TNF-alpha antibody marketed by Johnson & Johnson . But given the multitude of side effects and...